Transactivation of c-fos and beta-actin genes by raf as a step in early response to transmembrane signals - PubMed (original) (raw)
. 1990 Mar 29;344(6265):463-6.
doi: 10.1038/344463a0.
Affiliations
- PMID: 2157161
- DOI: 10.1038/344463a0
Transactivation of c-fos and beta-actin genes by raf as a step in early response to transmembrane signals
S Jamal et al. Nature. 1990.
Abstract
A primary response to many growth factor-induced transmembrane signals is the rapid activation of transcription of the proto-oncogene c-fos and other early-response genes, including the beta-actin gene. The c-raf gene encodes a cytoplasmic serine/threonine kinase, raf-1, whose activity is also responsive to transmembrane signals and which in mutant form can transform cells. Here we show that in transient assays, the v-raf protein, which is a constitutively activated oncogenic counterpart of raf-1, can transactivate transcription from two early-response promoters, including the c-fos promoter from human and murine cells and the human beta-actin gene promoter. Multiple elements of the human fos promoter, including the dyad symmetry element necessary for growth-factor induction, an octanucleotide direct repeat element, and the region spanning the sequence from nucleotides -225 to -99 can all serve as targets for raf induction. The c-myc promoter and two adenovirus-2 early promoters are not induced. These findings indicate that raf kinase, when activated by a transmembrane signal or by mutation of a regulatory domain, can phosphorylate a factor(s) capable of regulating transcription of the c-fos and actin genes. The oncogenic form of raf may transform by constitutively activating early response protooncogenes such as c-fos.
Similar articles
- v-raf confers CSF-1 independent growth to a macrophage cell line and leads to immediate early gene expression without MAP-kinase activation.
Büscher D, Dello Sbarba P, Hipskind RA, Rapp UR, Stanley ER, Baccarini M. Büscher D, et al. Oncogene. 1993 Dec;8(12):3323-32. Oncogene. 1993. PMID: 8247534 - Evidence that activation of the Egr-1 promoter by v-Raf involves serum response elements.
Rim M, Qureshi SA, Gius D, Nho J, Sukhatme VP, Foster DA. Rim M, et al. Oncogene. 1992 Oct;7(10):2065-8. Oncogene. 1992. PMID: 1408148 - v-Raf activates transcription of growth-responsive promoters via GC-rich sequences that bind the transcription factor Sp1.
Miltenberger RJ, Farnham PJ, Smith DE, Stommel JM, Cornwell MM. Miltenberger RJ, et al. Cell Growth Differ. 1995 May;6(5):549-56. Cell Growth Differ. 1995. PMID: 7647038 - Interactions between Ras and Raf: key regulatory proteins in cellular transformation.
Marshall M. Marshall M. Mol Reprod Dev. 1995 Dec;42(4):493-9. doi: 10.1002/mrd.1080420418. Mol Reprod Dev. 1995. PMID: 8607981 Review. - Signal integration at the c-fos promoter.
Janknecht R, Cahill MA, Nordheim A. Janknecht R, et al. Carcinogenesis. 1995 Mar;16(3):443-50. doi: 10.1093/carcin/16.3.443. Carcinogenesis. 1995. PMID: 7697796 Review. No abstract available.
Cited by
- Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups.
Perrone F, Mazzaschi G, Minari R, Verzè M, Azzoni C, Bottarelli L, Nizzoli R, Pluchino M, Altimari A, Gruppioni E, Sperandi F, Andrini E, Guaitoli G, Bertolini F, Barbieri F, Bettelli S, Longo L, Pagano M, Bonelli C, Tagliavini E, Nicoli D, Ubiali A, Zangrandi A, Trubini S, Proietto M, Gnetti L, Tiseo M. Perrone F, et al. Cancers (Basel). 2022 Apr 16;14(8):2019. doi: 10.3390/cancers14082019. Cancers (Basel). 2022. PMID: 35454926 Free PMC article. - Vemurafenib: the first drug approved for BRAF-mutant cancer.
Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P. Bollag G, et al. Nat Rev Drug Discov. 2012 Nov;11(11):873-86. doi: 10.1038/nrd3847. Epub 2012 Oct 12. Nat Rev Drug Discov. 2012. PMID: 23060265 Review. - Raf family kinases: old dogs have learned new tricks.
Matallanas D, Birtwistle M, Romano D, Zebisch A, Rauch J, von Kriegsheim A, Kolch W. Matallanas D, et al. Genes Cancer. 2011 Mar;2(3):232-60. doi: 10.1177/1947601911407323. Genes Cancer. 2011. PMID: 21779496 Free PMC article. - AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44.
Lamb RF, Hennigan RF, Turnbull K, Katsanakis KD, MacKenzie ED, Birnie GD, Ozanne BW. Lamb RF, et al. Mol Cell Biol. 1997 Feb;17(2):963-76. doi: 10.1128/MCB.17.2.963. Mol Cell Biol. 1997. PMID: 9001250 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous